Literature DB >> 30900101

The therapeutic potential of metformin in gastric cancer.

Sarah Courtois1, Philippe Lehours2,3, Emilie Bessède2,3.   

Abstract

Metformin is a biguanide molecule used since 1957 to treat type 2 diabetes patients. In addition to its hypoglycemic effects, epidemiological studies have shown that metformin can be associated with a decrease in cancer development risk in diabetic populations. Thus, since 2005 this molecule is largely studied for its antitumoural properties in different types of cancer. The potential antitumoural effect of metformin in gastric cancer has been poorly studied. Here, we detailed the different described mechanisms implicated in the antitumoural effect of metformin in gastric cancer, from the signalling pathways to the functional effects on gastric cancer cell lines and gastric cancer stem cells.

Entities:  

Keywords:  Cancer stem cells; EMT; Gastric adenocarcinoma; Tumour growth

Mesh：

Substances：

Year:  2019        PMID： 30900101     DOI： 10.1007/s10120-019-00952-w

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


  64 in total

1.  Metformin and reduced risk of cancer in diabetic patients.

Authors:  Josie M M Evans; Louise A Donnelly; Alistair M Emslie-Smith; Dario R Alessi; Andrew D Morris
Journal:  BMJ       Date:  2005-04-22

2.  Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line.

Authors:  Hiromasa Fujita; Katsumi Hirose; Mariko Sato; Ichitaro Fujioka; Tamaki Fujita; Masahiko Aoki; Yoshihiro Takai
Journal:  Oncol Lett       Date:  2018-12-24       Impact factor: 2.967

3.  Metformin targets gastric cancer stem cells.

Authors:  Sarah Courtois; Raúl V Durán; Julie Giraud; Elodie Sifré; Julien Izotte; Francis Mégraud; Philippe Lehours; Christine Varon; Emilie Bessède
Journal:  Eur J Cancer       Date:  2017-08-17       Impact factor: 9.162

4.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

Authors:  Marc Foretz; Sophie Hébrard; Jocelyne Leclerc; Elham Zarrinpashneh; Maud Soty; Gilles Mithieux; Kei Sakamoto; Fabrizio Andreelli; Benoit Viollet
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

Review 5.  Metformin in cancer: translational challenges.

Authors:  Ryan J O Dowling; Saroj Niraula; Vuk Stambolic; Pamela J Goodwin
Journal:  J Mol Endocrinol       Date:  2012-03-29       Impact factor: 5.098

6.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development.

Authors:  Na-Yu Chia; Niantao Deng; Kakoli Das; Dachuan Huang; Longyu Hu; Yansong Zhu; Kiat Hon Lim; Ming-Hui Lee; Jeanie Wu; Xin Xiu Sam; Gek San Tan; Wei Keat Wan; Willie Yu; Anna Gan; Angie Lay Keng Tan; Su-Ting Tay; Khee Chee Soo; Wai Keong Wong; Lourdes Trinidad M Dominguez; Huck-Hui Ng; Steve Rozen; Liang-Kee Goh; Bin-Tean Teh; Patrick Tan
Journal:  Gut       Date:  2014-07-22       Impact factor: 23.059

Review 8.  Survivin: A molecular biomarker in cancer.

Authors:  Praveen Kumar Jaiswal; Apul Goel; R D Mittal
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

9.  Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

Authors:  Guanzhen Yu; Wenzheng Fang; Tian Xia; Ying Chen; Yunshu Gao; Xiaodong Jiao; Suyun Huang; Jiejun Wang; Zhaosheng Li; Keping Xie
Journal:  Oncotarget       Date:  2015-05-20

10.  Negative regulation of Bmi-1 by AMPK and implication in cancer progression.

Authors:  Deqiang Huang; Xiaoling He; Junrong Zou; Pei Guo; Shanshan Jiang; Nonghua Lv; Yuriy Alekseyev; Lingyu Luo; Zhijun Luo
Journal:  Oncotarget       Date:  2016-02-02
View more
  13 in total

1.  Oral Azelaic Acid Ester Decreases Markers of Insulin Resistance in Overweight Human Male Subjects.

Authors:  Robert T Streeper; Elzbieta Izbicka; Christopher Louden
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.

Authors:  Zhiyong Shen; Dong Xue; Kun Wang; Facai Zhang; Jiaqi Shi; Benzhong Jia; Dan Yang; Qianjin Zhang; Shuai Zhang; Hongyu Jiang; Daiqin Luo; Xueying Li; Quliang Zhong; Junhao Zhang; Zheng Peng; Yu Han; Chongyang Sima; Xiaozhou He; Lin Hao
Journal:  BMC Urol       Date:  2022-05-24       Impact factor: 2.090

3.  Metformin Suppresses the Proliferation and Promotes the Apoptosis of Colon Cancer Cells Through Inhibiting the Expression of Long Noncoding RNA-UCA1.

Authors:  Jianbo Guo; Yan Li; He Duan; Lu Yuan
Journal:  Onco Targets Ther       Date:  2020-05-14       Impact factor: 4.147

Review 4.  Optimal management of coronary artery disease in cancer patients.

Authors:  Xue-Jie Han; Jian-Qiang Li; Zulfiia Khannanova; Yue Li
Journal:  Chronic Dis Transl Med       Date:  2020-01-14

5.  Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.

Authors:  Jun Lu; Bin-Bin Xu; Zhen Xue; Jian-Wei Xie; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Cancer Med       Date:  2020-12-03       Impact factor: 4.452

6.  Buformin suppresses osteosarcoma via targeting AMPK signaling pathway.

Authors:  Yan Ding; Shiqiao Lv; Guangrun Li; Jinpeng Cui; Yunzhen Chen
Journal:  Open Life Sci       Date:  2020-06-30       Impact factor: 0.938

7.  Potential effect of EGCG on the anti-tumor efficacy of metformin in melanoma cells.

Authors:  An'an Xu; Jeehyun Lee; Yueling Zhao; Yuefei Wang; Xiaoli Li; Ping Xu
Journal:  J Zhejiang Univ Sci B       Date:  2021-07-15       Impact factor: 3.066

Review 8.  Gastric carcinogenesis: a comprehensive review of the angiogenic pathways.

Authors:  Alicja Forma; Magdalena Tyczyńska; Paweł Kędzierawski; Klaudyna Gietka; Monika Sitarz
Journal:  Clin J Gastroenterol       Date:  2020-11-18

9.  The potential adjunctive benefit of adding metformin to standard treatment in inoperable cancer patients: a meta-analysis of randomized controlled trials.

Authors:  Zhonghua Wu; Bicheng Qu; Xuanzhang Huang; Yongxi Song; Peng Gao; Jinxin Shi; Cen Zhou; Zhenning Wang
Journal:  Ann Transl Med       Date:  2020-11

10.  CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer.

Authors:  Tongyuan Deng; Peng Shen; Aimin Li; Ziyan Zhang; Huiling Yang; Xiaojie Deng; Xuemei Peng; Zhe Hu; Zibo Tang; Jiahao Liu; Rentao Hou; Zhen Liu; Weiyi Fang
Journal:  Theranostics       Date:  2021-07-13       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.